Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Mar 16:5:46.
doi: 10.4103/2277-9175.178791. eCollection 2016.

The role of stem cell therapy in multiple sclerosis: An overview of the current status of the clinical studies

Rokhsareh Meamar  1 , Shahrzad Nematollahi  2 , Leila Dehghani  1 , Omid Mirmosayyeb  3 , Vahid Shayegannejad  4 , Keivan Basiri  4 , Amir Pouya Tanhaei  3
Affiliations
Review

The role of stem cell therapy in multiple sclerosis: An overview of the current status of the clinical studies

Rokhsareh Meamar et al. Adv Biomed Res. .

Retraction in

Abstract

The complexity of multiple sclerosis (MS) and the incompetence of a large number of promised treatments for MS urge us to plan new and more effective therapeutic approaches that aim to suppress ongoing autoimmune responses and induction of local endogenous regeneration. Emerging data propose that hematopoietic, mesenchymal, and neural stem cells have the potential to restore self-tolerance, provide in situ immunomodulation and neuroprotection, as well as promote regeneration. Thus, in this article, we will first provide an overview of the cell sources for proposed mechanisms that contribute to the beneficial effects of stem cell transplantation, the ideal route and/or timing of stem cell-based therapies for each main stem cell group, and finally, an overview of the current status of stem cell research in clinical trial stages in MS by comparable and healthy therapeutic effects of different stem cell therapies for MS patients.

Keywords: Cell therapy and transplantation; clinical trial; hematopoietic stem cells; mesenchymal stem cells; multiple sclerosis; neural stem/precursor cells; stem cells.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Connick P, Kolappan M, Crawley C, Webber DJ, Patani R, Michell AW, et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: An open-label phase 2a proof-of-concept study. Lancet Neurol. 2012;11:150–6. - PMC - PubMed
    1. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372:1502–17. - PubMed
    1. Giacomini PS, Darlington PJ, Bar-Or A. Emerging multiple sclerosis disease-modifying therapies. Curr Opin Neurol. 2009;22:226–32. - PubMed
    1. Meamar R, Karamali F, Sadeghi HM, Etebari M, Nasr-Esfahani MH, Baharvand H. Toxicity of ecstasy (MDMA) towards embryonic stem cell-derived cardiac and neural cells. Toxicol In Vitro. 2010;24:1133–8. - PubMed
    1. Meamar R, Dehghani L, Karamali F. Toxicity effects of methamphetamine on embryonic stem cell-derived neuron. J Res Med Sci. 2012;17:470–4. - PMC - PubMed